Rivaroxaban versus Apixaban for Treatment of Cancer-Associated Venous Thromboembolism in Patients at Lower Risk of Bleeding

Figures

• 

  Fig. 1. Patient inclusion and exclusion from the study. Of 14,618 patients with Ca-VTE initially identified, 12,181 were excluded, resulting in a final study population of 2,437 patients with cancer types for which oral factor Xa inhibitors are recommended according to guidelines and receiving either rivaroxaban or apixaban for inclusion in the analysis. Ca-VTE, cancer-associated venous thromboembolism; CNS, central nervous system.

• 

  Fig. 2. Time to recurrent VTE or bleeding-related hospitalization in rivaroxaban and apixaban patients. Kaplan–Meier curve for the composite of recurrent VTE or bleeding-related hospitalization (rivaroxaban = solid line, apixaban = dashed line). VTE, venous thromboembolism.

• 

  Fig. 3. Time to pneumonia (falsification outcome) in rivaroxaban and apixaban patients with Ca-VTE. Kaplan–Meier curve for the falsification outcome of pneumonia (rivaroxaban = solid line, apixaban = dashed line). Ca-VTE, cancer-associated venous thromboembolism.